ZVRA
Zevra Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +14.3% ·
share flow +30.0% ·
net new positions +12.5%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | +6 | 29.05M | $415.89M | +12 | −6 |
| Q1 2026 | 69 | 0 | 26.10M | $242.75M | +4 | −4 |
| Q4 2025 | 68 | +1 | 25.36M | $227.23M | +1 | n/a |
| Q3 2025 | 16 | +2 | 19.14M | $181.99M | +2 | n/a |
| Q2 2025 | 11 | 0 | 17.09M | $150.53M | n/a | n/a |
| Q1 2025 | 8 | 0 | 6.58M | $49.25M | +1 | −1 |
| Q4 2024 | 8 | +1 | 6.30M | $52.58M | +2 | −1 |
| Q3 2024 | 6 | +2 | 1.92M | $13.36M | +3 | −1 |
| Q2 2024 | 4 | n/a | 1.15M | $5.62M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 3.65M | +462.4% | $30.44M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.19M | +13.8% | $9.91M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 1.17M | n/a | $9.78M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 233.13K | +138.2% | $1.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 25.07K | New | $209,126 | 0.0% | New | 1 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 20.57K | +51.2% | $172,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 11.73K | New | $97,812 | 0.0% | New | 1 | SEC ↗ ×2 |
| 8 | Citadel Advisors ✦ | 2.49K | -96.3% | $20,758 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $209,126 | 0.0% |
| AQR Capital Management | $97,812 | 0.0% |
Exited
| Marshall Wace | $361,415 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 147 holders, 40.93M shares, $378.34M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 20.00K sh · $224,948
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology